Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models

被引：6
|
作者：
Borodovsky, Alexandra [1 ]
Wang, Yanjun [1 ]
Ye, Minwei [1 ]
Shaw, Joseph C. [1 ]
Sachsenmeier, Kris [1 ]
Deng, Nanhua [1 ]
Goodwin, Kelly [1 ]
Clarke, James D. [1 ]
Goodwin, Richard [1 ]
Strittmatter, Nicole [1 ]
Hay, Carl [2 ]
Sah, Vasu [1 ]
Deborah, Lawson [1 ]
Reimer, Corinne [1 ]
Congreve, Miles [3 ]
Mason, Jonathan [3 ]
Marshall, Fiona [3 ]
Lyne, Paul [1 ]
Woessner, Richard [1 ]
机构：
[1] AstraZeneca, Boston, MA USA
[2] MedImmune, Gaithersburg, MD USA
[3] Heptares Therapeut, Welwyn Garden City, Herts, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3751
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
    Willingham, Stephen
    Hotson, Andrew
    Ho, Po
    Choy, Carmen
    Walter, Kim
    Yusko, Erik
    Benzeno, Sharon
    Laport, Ginna
    Miller, Richard
    McCaffery, Ian
    CANCER RESEARCH, 2017, 77
  • [2] CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies
    Willingham, Stephen
    Hotson, Andrew
    Ho, Po
    Choy, Carmen
    Laport, Ginna
    McCaffery, Ian
    Miller, Richard
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [3] Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
    Borodovsky, Alexandra
    Barbon, Christine M.
    Wang, Yanjun
    Ye, Minwei
    Prickett, Laura
    Chandra, Dinesh
    Shaw, Joseph
    Deng, Nanhua
    Sachsenmeier, Kris
    Clarke, James D.
    Linghu, Bolan
    Brown, Giles A.
    Brown, James
    Congreve, Miles
    Cheng, Robert K. Y.
    Dore, Andrew S.
    Hurrell, Edward
    Shao, Wenlin
    Woessner, Richard
    Reimer, Corinne
    Drew, Lisa
    Fawell, Stephen
    Schuller, Alwin G.
    Mele, Deanna A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [4] Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
    Kim, Jeong M.
    CANCER RESEARCH, 2015, 75
  • [5] Anti-tumor immunity and efficacy of combination treatment of M6223 and bintrafusp alfa versus the combination of M6223 and anti-PD-L1 in preclinical tumor models
    Xu, Chunxiao
    Yalavarthi, Sireesha
    Bourin, Clotilde
    Kelton, Christie
    Halle, Joern-Peter
    Moisan, Jacques
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model
    Voronova, Veronika
    Peskov, Kirill
    Kosinsky, Yuri
    Helmlinger, Gabriel
    Chu, Lulu
    Borodovsky, Alexandra
    Woessner, Richard
    Sachsenmeier, Kris
    Shao, Wenlin
    Kumar, Rakesh
    Pouliot, Gayle
    Merchant, Melinda
    Kimko, Holly
    Mugundu, Ganesh
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] Anti-tumor and immune effects of olaparib plus /- anti-PD-L1 in preclinical BRCA1mut tumor models
    Staniszewska, Anna
    Armenia, Joshua
    King, Matthew
    Michaloglou, Chrysiis
    Singh, Maneesh
    San Martin, Maryann
    Wilson, Zena
    Proia, Theresa
    Delpuech, Oona
    O'Connor, Mark
    Leo, Elisabetta
    Valge-Archer, Viia
    CANCER RESEARCH, 2020, 80 (16)
  • [9] A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models
    Willingham, Stephen B.
    Ho, Po Y.
    Hotson, Andrew
    Hill, Craig
    Piccione, Emily C.
    Hsieh, Jessica
    Liu, Liang
    Buggy, Joseph J.
    McCaffery, Ian
    Miller, Richard A.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (10) : 1136 - 1149
  • [10] PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models
    Kenkel, Justin A.
    Gadkari, Rishali
    Ho, Po Y.
    Blum, Lisa K.
    Kudirka, Romas
    Henning, Karla A.
    Mallet, William G.
    Melrose, Jennifer E.
    Sarma, Ganapathy
    Chapin, Steven J.
    Zhou, Matthew
    Deol, Suprit
    Kreder, Cindy
    Shen, Yuyi
    Hug, Bruce
    Anand, Puneet
    Lee, Arthur
    Li, Hai
    Ackerman, Shelley E.
    Safina, Brian S.
    Dornan, David
    Alonso, Michael N.
    Kowanetz, Marcin
    CANCER RESEARCH, 2022, 82 (12)
12345